Navigation Links
Savient Pharmaceuticals Announces Closing of Public Offering and Exercise of Over-Allotment Option
Date:10/15/2009

EAST BRUNSWICK, N.J., Oct. 15 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced today the closing of its previously announced underwritten public offering. Prior to closing, the underwriters exercised in full their option to purchase an additional 645,000 shares of common stock. As a result, Savient sold a total of 4,945,000 shares of its common stock at a price to the public of $13.29 per share. After underwriting discounts and commissions and estimated offering expenses, Savient received net proceeds of approximately $60.9 million. These shares were sold pursuant to Savient's existing shelf registration statement, the prospectus contained therein and the prospectus supplement as filed with the Securities Exchange Commission.

Savient intends to use the net proceeds from this offering to complete its effort to seek FDA approval of KRYSTEXXA(TM) (pegloticase), to develop a program of regulatory filings and review of KRYSTEXXA in other countries, to engage a global secondary source supplier and a secondary fill and finish manufacturer for pegloticase, and for working capital and other general corporate purposes.

J.P. Morgan Securities Inc. acted as sole book-running manager of the offering, with Wedbush PacGrow Life Sciences as lead manager and Lazard Capital Markets as co-manager. Copies of the final prospectus supplement and accompanying prospectus may be obtained by contacting J.P. Morgan Securities Inc., Attention: Prospectus Department, 4 Chase Metrotech Center, CS Level, Brooklyn, NY 11245.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.

ABOUT SAVIENT PHARMACEUT
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Savient Pharmaceuticals Prices Underwritten Offering of Common Stock
2. Savient Pharmaceuticals Announces Proposed Public Offering of Common Stock
3. Savient Provides Update on Pegloticase BLA
4. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
5. Access Pharmaceuticals Provides Update on MuGard Commercial Launch and First European Clinicians Feedback
6. Data from Jazz Pharmaceuticals First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia to be Presented at Upcoming Conferences
7. Timm Medical Technologies and Ferring Pharmaceuticals Enter Exclusive Co-Promotion Agreement for Prosed(R) DS
8. China Yongxin Pharmaceuticals Inc. Announces Second Quarter 2009 Financial Results
9. VIA Pharmaceuticals Receives Favorable Hearing Decision From NASDAQ
10. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
11. Vion Pharmaceuticals Engages Merriman Curhan Ford to Evaluate Strategic Alternatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2010)... February 9 Debiopharm Group,(Debiopharm), ... with,a focus on the development of prescription ... the signature of an exclusive licence agreement ... of Debio 025,(alisporivir), a selective, first-in-class cyclophilin ... (HCV) effect. The product is currently in ...
(Date:2/8/2010)... FRANKLIN LAKES, N.J. , Feb. 8 /PRNewswire/ ... and Company), announced today the launch of BD Microtainer® ... new product is designed to improve the safety, accuracy ... in patients with veins that can be difficult to ... elderly. The new BD Microtainer MAP product is also ...
(Date:2/8/2010)... Sagent Pharmaceuticals, Inc., a privately held ... received FDA approval of labetalol hydrochloride (HCl) injection, ... product will be available in two vial sizes ... mg per 40 mL, multi-dose vials.  According to ... Americans have hypertension, or high blood pressure.  IMS ...
Breaking Medicine Technology:Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025 2Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025 3BD Launches New Device Designed to Improve Safety, Accuracy and Turnaround Time of Blood Collection in Patients with Fragile Veins 2Sagent Pharmaceuticals Announces FDA Approval of Labetalol Hydrochloride Injection, USP 2Sagent Pharmaceuticals Announces FDA Approval of Labetalol Hydrochloride Injection, USP 3New and Updated Online Tutorials for ArrayExpress Allen Brain Atlas and CleanEx from OpenHelix 54389 1New and Updated Online Tutorials for ArrayExpress Allen Brain Atlas and CleanEx from OpenHelix 54389 2New and Updated Online Tutorials for ArrayExpress Allen Brain Atlas and CleanEx from OpenHelix 54389 3Cancer Mortality Rates Experience Steady Decline 54386 1Cancer Mortality Rates Experience Steady Decline 54386 2Cancer Mortality Rates Experience Steady Decline 54386 3Cancer Mortality Rates Experience Steady Decline 54386 4APHL Chosen by PEPFAR to Develop Global Health Laboratory Systems 54384 1APHL Chosen by PEPFAR to Develop Global Health Laboratory Systems 54384 2
... May 31 Eli Lilly and Company announced today ... Lilly,s GEMZAR(R) (gemcitabine HCl for injection) to the current ... progression-free survival at three years for women with locally ... second most commonly diagnosed women,s cancer, and the second ...
... than double risk of cancer recurrence in tamoxifen treated ... drugs that reduce its effectiveness against breast cancerORLANDO, Fla., ... certain popular antidepressants frequently prescribed to women taking the ... of a breast cancer recurrence for those using both ...
Other Medicine Technology:Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients 2Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients 3Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients 4Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients 5Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients 6New Study: Antidepressants Commonly Prescribed with Tamoxifen Put Women at Much Higher Risk for Recurrent Breast Cancer 2New Study: Antidepressants Commonly Prescribed with Tamoxifen Put Women at Much Higher Risk for Recurrent Breast Cancer 3New Study: Antidepressants Commonly Prescribed with Tamoxifen Put Women at Much Higher Risk for Recurrent Breast Cancer 4New Study: Antidepressants Commonly Prescribed with Tamoxifen Put Women at Much Higher Risk for Recurrent Breast Cancer 5
(Date:2/9/2010)... vitamin D begins in the womb, expert says, , , ... mothers who drink lots of milk and have a ... a much lower risk of developing multiple sclerosis later ... 35,794 U.S. nurses whose mothers provided information about their ... for 16 years, and 199 of them developed multiple ...
(Date:2/9/2010)... blood pressure restrict fetal growth, study finds, , , TUESDAY, ... bring into pregnancy can have lasting effects on your ... found that women who smoked, had high blood pressure ... babies that were smaller in the first trimester of ... , "Our study demonstrates that several maternal physical characteristics ...
(Date:2/9/2010)... Insurer-favored ,Cost Solution,: Selling Policies That Amount To ,A ... WASHINGTON , Feb. 9 Blue ... with its premium hikes of up to 39% in ... of questions from the White House and an investigation ... lawmakers should act to regulate health insurance premiums and ...
(Date:2/9/2010)... , Feb. 9 ... J. James Rohack , M.D., President, American ... ,, "The American Medical Association is ... Obama in the Let,s Move Campaign. ... have long worked to address obesity and ...
(Date:2/9/2010)... Institute and the Sanford-Burnham Medical Research Institute have ... owned member of the Roche group, and Roche, ... develop and market human monoclonal antibodies to treat ... viruses include the strains for the current seasonal ... a non-exclusive right to manufacture, develop and market ...
Breaking Medicine News(10 mins):Health News:Drinking Milk While Pregnant May Lower Kids' MS Risk 2Health News:Mom's Lifestyle in Early Pregnancy Affects Baby's Size 2Health News:Mom's Lifestyle in Early Pregnancy Affects Baby's Size 3Health News:Blue Cross Claim That 39% Premium Hikes Due Only to 'Escalating Cost of Health Care' Trigger Calls for Regulation of Rates 2Health News:Blue Cross Claim That 39% Premium Hikes Due Only to 'Escalating Cost of Health Care' Trigger Calls for Regulation of Rates 3
... of parents will be required by teenagers in Scotland who ... tattoo studios will also be subject to mandatory licensing// to ... to all those who are less than 16 years of ... the possibilities of blood borne diseases being transmitted through contaminated ...
... mother Bernadette Mimura, belonging to Ingleby Barwick Ingleby Barwick who ... disease//. She had refused life-saving treatment as it involved making ... the unborn baby, by the doctors. ,Being a ... a mild form of chemotherapy treatment with the object of ...
... to feel happy about the way he looks by just looking ... looks great he is convinced//. ,Women on the other ... difficult to satisfy them unless they are supplemented with actual results. ... was conducted by Kathleen Martin Ginis, associate professor of kinesiology at ...
... that moderate exercise has positive benefits on the hearts, ... studies in the last 10 to 20 years have ... people suffering from congestive heart failure. ,However, the ... to be statistically significant. ,In the new study ...
... on the Gulf of Carpentaria in Australia has triggered concerns ... virus//. ,However, the Australian Quarantine and Inspection Service ... they were sending out a team as a precautionary measure, ... a military operative has also started towards the island. "There's ...
... has been found to be effective in treatment of ... benefited from vitamin treatment as found by researchers from ... intervention wherein patients not responsive to steroid treatment after ... ,Professor Tak Lee, Director of the MRC-Asthma UK ...
Other Medicine News:Health News:Asthma an be treated with Vitamin supplement intervention 2
This product is for the lower body and uses a Convective Warming System which is both soft and comfortable. Constructed of 2-ply material consisting of polyethylene film inner layer and non-woven out...
The torso blanket is designed to affix to the lower abdominal area and cover the upper half of the body....
The fabric is antistatic and non-linting and is both oil and water repellent.These superior blankets are an environmental friendly alternative to disposable blankets....
CritiCool™ offers precise cooling to the programmed target temperature by applying temperature control algorithm....
Medicine Products: